Skip to content
lifestyle.luxedb.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nuvectis Pharma, Inc.
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
September 24, 2026
Nuvectis Pharma To Participate in Upcoming Investor Conferences
September 3, 2026
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
August 4, 2026
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
July 23, 2026
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
July 23, 2026
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
June 29, 2026
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
June 29, 2026
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
June 22, 2026
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 14, 2026
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
May 5, 2026
1
2
Next Page
→